Longer Duration of Treatment with ICIs Associated with a Higher Rate of Complete Response Among Patients with MMRd Cancers By Ogkologos - March 5, 2025 740 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a systematic review of published studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR Six Months Immunogenicity of COVID-19 mRNA-based Vaccine in Patients with Actively... December 14, 2021 Fostering Growth and Creativity Through Journaling August 11, 2021 Advancing Patient Care Through Focused Innovation April 16, 2018 FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma May 23, 2025 Load more HOT NEWS Five Questions With…Jessica, Katie, and Melanie How Music Can Help You Cope During Cancer: An Expert Perspective EMA Recommends Extension of Indications for Pirtobrutinib Girl’s New College Dorm Has Perfect View Of The Hospital Room...
